CONVELL LABORATORIES
Pharmaceutical company · 27 brands · 25 molecules
Ranked #81 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)
Company overview
CONVELL LABORATORIES is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 27 product registrations across 25 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Quinolone Antibacterials. It has no DRAP recall, shortage or safety notices on record.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Top molecules by brand count
Therapeutic classes
Price band (DRAP official ceilings)
Regulatory record
No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Get the full profile for CONVELL
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included